v3.25.2
Shareholders' Equity (Tables)
 6 Months Ended
Jun. 30, 2025
Equity [Abstract]  
Schedule of the Stock Option and RSU Award Activities
The following table summarizes the stock option and Restricted Share Unit ("RSU") award activities under the Company's share-based compensation plans for the six months ended June 30, 2025:
Shares Subject to Options OutstandingOutstanding RSUs
Number of Options(1)
Weighted Average Exercise PriceRemaining Contractual Term (in years)
Aggregate Intrinsic Value(2)
Weighted Average Grant Date Fair ValueOutstanding RSUsWeighted Average Grant Date Fair Value
(in US $ millions, except share and share price amounts)
December 31, 202414,636,992 64.497.68623 — 5,121,069 74.90 
Stock options granted1,577,868 121.97— — 63.33 — — 
Stock options exercised(2,323,439)44.16— — — — — 
Stock options forfeited(141,620)63.64— — — — — 
RSUs granted— —— — — 2,376,907 107.54 
RSUs settled— —— — — (2,212,348)80.32 
RSUs forfeited— —— — — (261,711)74.93 
June 30, 202513,749,801 74.537.59608 — 5,023,917 87.96 
Stock options exercisable as of June 30, 2025
6,290,283 64.626.08351 
(1) As of June 30, 2025, nil of the outstanding stock options were granted under the Company's Fourth Amended and Restated Stock Option Plan ("Legacy Option Plan") and there are no longer any outstanding stock options granted under the Legacy Option Plan, 13,712,770 of the outstanding stock options were granted under the Company's SOP and are exercisable for Class A subordinate voting shares, and 37,031 of the outstanding stock options were granted under the Deliverr 2017 Stock Option and Grant Plan and are exercisable for Class A subordinate voting shares.
(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's Class A subordinate voting shares as of June 30, 2025 and December 31, 2024.
Schedule of Classification of Stock-based Compensation
The following table illustrates the classification of stock-based compensation expense in the condensed consolidated statements of operations and comprehensive income (loss), which includes both stock-based compensation and restricted stock-compensation expense:
Three months ended June 30,Six months ended June 30,
2025202420252024
(in US $ millions)
Cost of revenues1324
Sales and marketing11102321
Research and development8070159138
General and administrative21234348
113106227211